Remove Medicine Remove Reagent Remove Sales
article thumbnail

Swittons Introduces Smart IoT Devices for Pharmaceutical Lab Digital Transformation Initiatives

pharmaphorum

Driven by technological advances and the development of precision medicines, these modernization initiatives are designed to propel laboratory efficiencies into the future, allowing scientists to spend more time on science. Reorder reagents. Notify of spill/cleaning needed. Equipment occupancy notification. Summon a lab runner.

article thumbnail

Are microtaggants the key to making medicines smarter?

pharmaphorum

Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. Specific apps could also alert healthcare providers if vulnerable patients are failing to scan their medicine. This technology can also play an important role in supporting virtual clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading API biologics (protein and peptide) companies in contract marketing

Pharmaceutical Technology

Emerging technologies such as 3D printing and bioprinting, electrospinning, electrospraying, microfluidics, nanofluidics, microelectromechanical, and bio-electromechanical systems are being utilised to prepare systems for the delivery of personalised medicine, meeting patient’s needs, and developing old drugs with new processes.

Protein 100
article thumbnail

Asia-Pacific Roundup: New Zealand bans unapproved COVID vaccines

The Pharma Data

The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has banned the trade in unapproved COVID-19 vaccines for a year to prevent the use of vaccines that may not be safe or effective. . TGA warns of unlawful advertising of listed medicines. Medsafe framed the action in the context of public safety. . “In

Vaccine 52
article thumbnail

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

FDA Law Blog

The PR first sets out to establish that it has authority to regulate in vitro diagnostic “test systems” as devices, and not just the system’s individual components, such as reagents, instruments, specimen collection devices, and software. The PR states that LDTs are not the “practice of medicine,” with which FDA generally may not interfere.

article thumbnail

New Sandoz Board of Directors appointed

The Pharma Data

She is also a board member at BBI Solutions, a UK based diagnostic reagents and a Novo Holdings company. Shamiram holds an AB from Smith College and Doctor of Medicine as well as a Master of Public Health, both from Emory University, U.S.A.

Sales 40
article thumbnail

Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients

The Pharma Data

The test offers an alternative to lab-developed tests (LDTs) or Assay Specific Reagents (ASR) combinations, potentially minimising variability and complexity in testing, reducing workload and alleviating risk for laboratories. billion in R&D and posted sales of CHF 61.5 In 2019, Roche invested CHF 11.7

DNA 52